Togo

Region: West Africa

Key information on co-financing

- Gross National Income per capita (2017): $610
- Co-financing status (2019): Initial self-financing
- Country is projected to stay in initial self financing phase for next 5 years.

Immunisation financing

<table>
<thead>
<tr>
<th>Vaccines used in routine immunisation</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Government expenditure</td>
<td>$1,063,830</td>
<td>$920,000</td>
<td>$543,422</td>
<td>$445,686</td>
<td>$561,763</td>
</tr>
<tr>
<td>- Total expenditure</td>
<td>$2,523,752</td>
<td>$3,092,880</td>
<td>$4,748,738</td>
<td>$4,737,557</td>
<td>$3,271,982</td>
</tr>
<tr>
<td>- Government as % of total</td>
<td>42%</td>
<td>30%</td>
<td>11%</td>
<td>9%</td>
<td>17%</td>
</tr>
</tbody>
</table>

Routine immunisation

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Type</th>
<th>Year(s) of Gavi support</th>
<th>Co-financing required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yellow Fever</td>
<td>Routine</td>
<td>2002-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Pentavalent</td>
<td>Routine</td>
<td>2008-present</td>
<td>Yes</td>
</tr>
<tr>
<td>PCV</td>
<td>Routine</td>
<td>2014-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Routine</td>
<td>2014-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Meningitis A</td>
<td>Campaign</td>
<td>2014</td>
<td>No</td>
</tr>
<tr>
<td>HPV</td>
<td>Demonstration</td>
<td>2014-2015</td>
<td>No</td>
</tr>
<tr>
<td>IPV</td>
<td>Routine</td>
<td>2018 introduction</td>
<td>No</td>
</tr>
<tr>
<td>Yellow Fever</td>
<td>Campaign</td>
<td>2007</td>
<td>No</td>
</tr>
<tr>
<td>MR</td>
<td>Campaign</td>
<td>2018</td>
<td>No</td>
</tr>
</tbody>
</table>

Gavi supported vaccines

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Type</th>
<th>Year(s) of Gavi support</th>
<th>Co-financing required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yellow Fever</td>
<td>Routine</td>
<td>2002-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Pentavalent</td>
<td>Routine</td>
<td>2008-present</td>
<td>Yes</td>
</tr>
<tr>
<td>PCV</td>
<td>Routine</td>
<td>2014-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Routine</td>
<td>2014-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Meningitis A</td>
<td>Campaign</td>
<td>2014</td>
<td>No</td>
</tr>
<tr>
<td>HPV</td>
<td>Demonstration</td>
<td>2014-2015</td>
<td>No</td>
</tr>
<tr>
<td>IPV</td>
<td>Routine</td>
<td>2018 introduction</td>
<td>No</td>
</tr>
<tr>
<td>Yellow Fever</td>
<td>Campaign</td>
<td>2007</td>
<td>No</td>
</tr>
<tr>
<td>MR</td>
<td>Campaign</td>
<td>2018</td>
<td>No</td>
</tr>
</tbody>
</table>

Co-financing payments

<table>
<thead>
<tr>
<th>Total amount paid by the country</th>
<th>Co-financed vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008 $75,000</td>
<td>Penta</td>
</tr>
<tr>
<td>2009 $145,000</td>
<td>Penta</td>
</tr>
<tr>
<td>2010 $168,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2011 $168,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2012 $244,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2013 $188,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2014 $553,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2015 $562,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2016 $449,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2017 $446,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2018 $805,000</td>
<td>Penta Yellow Fever</td>
</tr>
</tbody>
</table>

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: 0.47%

Source: WHO National Health Accounts, 2015

Gavi supported vaccines

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Type</th>
<th>Year(s) of Gavi support</th>
<th>Co-financing required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yellow Fever</td>
<td>Routine</td>
<td>2002-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Pentavalent</td>
<td>Routine</td>
<td>2008-present</td>
<td>Yes</td>
</tr>
<tr>
<td>PCV</td>
<td>Routine</td>
<td>2014-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Routine</td>
<td>2014-present</td>
<td>Yes</td>
</tr>
<tr>
<td>Meningitis A</td>
<td>Campaign</td>
<td>2014</td>
<td>No</td>
</tr>
<tr>
<td>HPV</td>
<td>Demonstration</td>
<td>2014-2015</td>
<td>No</td>
</tr>
<tr>
<td>IPV</td>
<td>Routine</td>
<td>2018 introduction</td>
<td>No</td>
</tr>
<tr>
<td>Yellow Fever</td>
<td>Campaign</td>
<td>2007</td>
<td>No</td>
</tr>
<tr>
<td>MR</td>
<td>Campaign</td>
<td>2018</td>
<td>No</td>
</tr>
</tbody>
</table>

Co-financing payments

<table>
<thead>
<tr>
<th>Total amount paid by the country</th>
<th>Co-financed vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008 $75,000</td>
<td>Penta</td>
</tr>
<tr>
<td>2009 $145,000</td>
<td>Penta</td>
</tr>
<tr>
<td>2010 $168,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2011 $168,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2012 $244,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2013 $188,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2014 $553,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2015 $562,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2016 $449,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2017 $446,000</td>
<td>Penta Yellow Fever</td>
</tr>
<tr>
<td>2018 $805,000</td>
<td>Penta Yellow Fever</td>
</tr>
</tbody>
</table>
Co-financing obligations for 2019

<table>
<thead>
<tr>
<th></th>
<th>Co-financing obligations (in US$)</th>
<th>Co-financing obligations (in doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>YF</td>
<td>$70,500</td>
<td>57,600</td>
</tr>
<tr>
<td>Rota</td>
<td>$112,500</td>
<td>49,500</td>
</tr>
<tr>
<td>PCV</td>
<td>$171,500</td>
<td>57,400</td>
</tr>
<tr>
<td>Pentavalent</td>
<td>$198,000</td>
<td>278,000</td>
</tr>
<tr>
<td>MR</td>
<td>$126,500</td>
<td>194,300</td>
</tr>
<tr>
<td>Total</td>
<td>$679,000</td>
<td></td>
</tr>
</tbody>
</table>

Co-financing projections for 2020 - 2024

- Projections are based on Gavi’s operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country’s application.
- Final co-financing obligations will be communicated through decision letters.